Skip to content
Somatostatin
Somatostatin is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01C: Hypothalamic hormones
— H01CB: Somatostatin and analogues
— H01CB01: Somatostatin
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.0———167
Portal hypertensionD006975EFO_0000666K76.61—1125
AcromegalyD000172—1—124
Neuroendocrine tumorsD018358EFO_1001901D3A.8——1124
Esophageal and gastric varicesD004932EFO_0009545I85———134
Healthy volunteers/patients—1——2—3
HemorrhageD006470MP_0001914R58———123
End stage liver diseaseD058625EFO_1001311K72.1———1—1
Acute necrotizing pancreatitisD019283———1—1
FibrosisD005355———1—1
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver neoplasmsD008113EFO_1001513C22.0——2——2
Autosomal dominant polycystic kidneyD016891EFO_1001496Q61.2——1——1
Gallbladder neoplasmsD005706EFO_0004606C23——1——1
Malignant carcinoid syndromeD008303E34.0——1——1
Pancreatic diseasesD010182K86.9—11——1
Liver failureD017093HP_0001399K72.9——1——1
PancreatitisD010195EFO_0000278K85——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E10—1——12
Carcinoid tumorD002276D3A.00—1———1
Islet cell carcinomaD018273C25.4—1———1
Peptic ulcerD010437HP_0004398K27—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoglycemiaD007003HP_0001943E16.21———23
Prostatic neoplasmsD011471C611————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Glomerular filtration rateD005919EFO_0005208————11
Renal circulationD012079————11
Renal plasma flowD017595————11
Insulin resistanceD007333EFO_0002614————11
Glucose intoleranceD018149HP_0000833R73.03————11
Laron syndromeD046150Orphanet_633E34.321————11
Acute kidney injuryD058186HP_0001919N17————11
Venous thrombosisD020246HP_0004936I82.40————11
Varicose veinsD014648HP_0002619I83.90————11
Neuroendocrine carcinomaD018278————11
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSOMATOSTATIN
INNsomatostatin
Description
SOMATOSTATIN
Classification
Protein
Drug classgrowth hormone derivatives; enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O
Identifiers
PDB—
CAS-ID38916-34-6
RxCUI—
ChEMBL IDCHEMBL1823872
ChEBI ID64628
PubChem CID—
DrugBank—
UNII ID6E20216Q0L (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 50,946 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
75 adverse events reported
View more details